ENRYLAZE 10 mg/0.5 ml, solution for injection/for infusion 3 bottles of 0.5 ml
Active ingredients: CRISANTASPASE RECOMBINANTE
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Solution for injection or infusion3 bottles of 0.5 mlintramusculaire;intraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ENRYLAZE 10 mg/0,5 mL, solution injectable/pour perfusion
- Pharmaceutical form
- solution injectable ou pour perfusion
- Route of administration
- intramusculaire;intraveineuse
- Presentation description
- 3 flacon(s) en verre de 0,5 ml
- Marketing authorisation holder
- JAZZ PHARMACEUTICALS IRELAND LIMITED (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 19 Nov 2024
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
67034579CIP75509868CIP133400955098683Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CRISANTASPASE RECOMBINANTEsolution | 10 mg · un flacon de 0,5 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.